Merck reports Q3 earnings on Oct. 29 with KEYTRUDA's 2028 patent clock ticking louder, and whether LIPFENDRA, QLEX, and ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...
Tampa Free Press on MSN
On high alert: Uganda imposes strict Ebola quarantine after airport transit cases emerge
Ugandan citizens returning from the Democratic Republic of Congo must undergo a mandatory 21-day quarantine as authorities ...
Personalized Moderna and Merck vaccine, called intismeran, was made with same Nobel Prize-winning mRNA technology behind ...
As assessed by blinded independent central review (BICR), the objective response rate was 50.2% and 47.3% in the two groups, ...
After 100 years, there's finally an effective cancer vaccine. Now comes the push to get them to work in more tumor types.
In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...
A Roche Holding AG drug billed as a potential blockbuster helped patients with a form of lung cancer that had spread live ...
Healthcare stocks outperformed as Wall Street fell. See top healthcare winners and losers, Moderna data fallout, and major pharma deals—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results